DLBCLdiffuse large B-cell lymphoma
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
It is important to identify, measure, and interpret the characteristics of alterations which have prognostic implications and influence in a DLBCL patient's survival.
We systematically reviewed the clinical and pathological features of all CD 20 negative DLBCL lymphoma patients diagnosed at our institution over the last 13 years.
Histologically, DLBCLs exhibit a diffuse effacement of the normal architecture by a submucosal, discohesive cellular infiltrate (figure 1).
Few studies have reported the use of immunohistochemical expression of CD10, Bcl-6, and/or MUM1 to classify cases of DLBCL into GC and non-GC subtypes in ARL patients.
MTEM is conducting a Phase II monotherapy study of MT-3724 in relapsed/refractory DLBCL. This study has the potential to serve as a registration study.
Yescarta was the first CAR T cell therapy to be approved by the United States Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified, primary mediastinal large B-cell lymphoma, and high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.
A 27-years old lactating female, diagnosed with DLBCL, underwent staging PET-CT scan.
Background: Prospective real-life data on the safety and effectiveness of rituximab in Chinese patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) are limited.